Want to see FR:DBV full AI Analyst Report?
Top Page
DBV Technologies
(DBV)
Select Model
Select Model
Rating:43Neutral
Price Target:
€1.50
▼(-36.71% Downside)
Action:Reiterated
Date:10/07/26
The score is driven primarily by very weak financial performance (heavy losses and significant free-cash-flow burn), only partially offset by a relatively low-debt balance sheet. Technicals add downside pressure with a clear downtrend below major moving averages and negative MACD, while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Low leverage
Debt of about €7.7M against €160.5M of equity indicates limited leverage, while assets of roughly €223.2M are primarily equity-funded. This provides greater solvency resilience and financial flexibility than a heavily indebted biotech as development spending continues.
Negative Factors
Severe operating losses
Minimal revenue combined with very large operating and net losses shows that DBV has not yet established economic scale. Persistently negative profitability limits internal funding capacity, increases reliance on capital raising, and raises the risk of continued shareholder capital erosion.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Debt of about €7.7M against €160.5M of equity indicates limited leverage, while assets of roughly €223.2M are primarily equity-funded. This provides greater solvency resilience and financial flexibility than a heavily indebted biotech as development spending continues.
Read all positive factors
DBV Technologies (DBV) vs. iShares MSCI France ETF (EWQ)
Market Cap
€563.28M
Dividend YieldN/A
Average Volume (3M)1.15M
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue GrowthN/A
EPS Growth41.33%
CountryFR
Employees170
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.78
Shares Outstanding314,388,800
10 Day Avg. Volume1,077,558
30 Day Avg. Volume1,151,140
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.28
Price to Sales (P/S)0.00
P/FCF Ratio-4.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)€2.33M
DBV Technologies Business Overview & Revenue Model
Company Description
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical...
How the Company Makes Money
DBV Technologies does not have product revenue from commercialized therapies and primarily finances operations through external funding rather than sales. Its main sources of funds typically include (1) proceeds from equity financings (e.g., publi...
DBV Technologies Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
63
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.73M | 0.00 | 4.15M | 15.73M | 25.07M | 5.71M |
| Gross Profit | -7.00M | -18.34M | 4.15M | 15.73M | 4.77M | -3.57M |
| EBITDA | -177.30M | -140.58M | -109.75M | -61.37M | -83.47M | -80.67M |
| Net Income | -176.26M | -152.94M | -113.92M | -72.73M | -96.27M | -97.81M |
Balance Sheet | ||||||
| Total Assets | 223.20M | 233.75M | 65.66M | 183.04M | 246.40M | 146.72M |
| Cash, Cash Equivalents and Short-Term Investments | 174.90M | 194.19M | 32.46M | 141.37M | 209.20M | 77.30M |
| Total Debt | 21.80M | 7.99M | 6.95M | 5.67M | 3.02M | 9.74M |
| Total Liabilities | 62.80M | 64.96M | 38.27M | 43.02M | 52.13M | 47.45M |
| Stockholders Equity | 160.50M | 168.79M | 27.39M | 140.19M | 194.50M | 99.27M |
Cash Flow | ||||||
| Free Cash Flow | -170.70M | -126.68M | -106.81M | -80.33M | -56.45M | -109.16M |
| Operating Cash Flow | -169.40M | -126.12M | -104.47M | -79.65M | -55.70M | -108.24M |
| Investing Cash Flow | -1.86M | -1.42M | -757.00K | -786.62K | -100.00K | -433.00K |
| Financing Cash Flow | 248.19M | 287.44M | 587.00K | 6.77M | 194.10M | 274.00K |
DBV Technologies Technical Analysis
Neutral
2.37
Price Trends
2.08
Negative
2.37
Negative
2.96
Negative
Market Momentum
-0.10
Negative
46.20
Neutral
88.34
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:DBV, the sentiment is Neutral. The current price of 2.37 is above the 20-day moving average (MA) of 1.76, above the 50-day MA of 2.08, and below the 200-day MA of 2.96, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 46.20 is Neutral, neither overbought nor oversold. The STOCH value of 88.34 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:DBV.
DBV Technologies Risk Analysis
DBV Technologies disclosed 78 risk factors in its most recent earnings report. DBV Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
DBV Technologies Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | €944.71M | -28.90 | ― | ― | -23.21% | -50.69% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | €145.43M | -2.55 | 152.56% | ― | -29.48% | 7.91% | |
47 Neutral | €189.23M | -4.07 | -29.36% | ― | 189.81% | 38.50% | |
47 Neutral | €460.23M | -2.69 | -152.15% | ― | -27.19% | -117.39% | |
43 Neutral | €563.28M | -2.57 | -119.47% | ― | ― | 41.33% | |
41 Neutral | €48.42M | -1.22 | -96.73% | ― | -96.25% | -197.89% |
* General Sector Average
FR:DBV
DBV Technologies
1.79
-0.92
-34.00%
FR:IPH
Innate Pharma SA
1.30
-0.39
-22.96%
FR:TNG
Transgene
0.68
-0.69
-50.36%
FR:VLA
Valneva
2.42
-1.48
-37.97%
FR:OSE
OSE Immunotherapeutics SA
2.06
-3.82
-65.00%
FR:MEDCL
MedinCell SA
26.30
-10.82
-29.15%
DBV Technologies Corporate Events
DBV Technologies Files BLA with FDA for VIASKIN Peanut Patch in Children
Sep 29, 2026
DBV Technologies has submitted a Biologics License Application to the U.S. Food and Drug Administration for its VIASKIN Peanut patch, targeting peanut-allergic children aged four to seven years. The company is seeking priority review for the non-i...
DBV Technologies Steps Up Investor Outreach Ahead of Key Food Allergy Trial Milestones
Sep 3, 2026
DBV Technologies will engage investors at three major healthcare and biopharma conferences in New York this September, including events hosted by Cantor, Citi, and H.C. Wainwright, featuring fireside chats and one-on-one meetings. The company will...
DBV Technologies Updates Share Capital and Voting Rights as of August 31, 2026
Sep 2, 2026
DBV Technologies reported that its share capital comprised 314,388,807 shares as of August 31, 2026, corresponding to an equal gross total of voting rights. The company disclosed a slightly lower net total of voting rights at 314,222,095, reflecti...
DBV Technologies Raises $50 Million via Nasdaq ATM Share Sale
Jul 30, 2026
DBV Technologies has raised approximately $50 million through the sale of new American Depositary Shares on Nasdaq under its at-the-market program, issuing 18,288,220 new ordinary shares underlying 3,657,644 ADSs to RA Capital Management via Citiz...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.